Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 55% Improvement Relative Risk Ventilation 69% Hospitalization 77% Antiandrogens for COVID-19  Patel et al.  Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective 58 patients in the USA (March - June 2020) Lower hospitalization with antiandrogens (p=0.02) c19early.org Patel et al., Annals of Oncology, July 2020 Favors various Favors control

Does androgen deprivation therapy protect against severe complications from COVID-19?

Patel et al., Annals of Oncology, doi:10.1016/j.annonc.2020.06.023
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
7th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 58 prostate cancer patients in the USA, showing lower risk of hospitalization with ADT.
risk of death, 55.2% lower, RR 0.45, p = 0.22, treatment 4 of 22 (18.2%), control 10 of 36 (27.8%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of mechanical ventilation, 69.0% lower, OR 0.31, p = 0.19, treatment 22, control 36, adjusted per study, multivariable, RR approximated with OR.
risk of hospitalization, 77.0% lower, OR 0.23, p = 0.02, treatment 22, control 36, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 9 Jul 2020, retrospective, USA, peer-reviewed, 7 authors, study period 1 March, 2020 - 4 June, 2020.
This PaperAntiandrogensAll
Abstract: Annals of Oncology Letters to the Editor investigation, including antiviral drugs, we suggest that convalescent plasma could be useful in patients with COVID19 infection and concurrent persistent B-cell immunodeficiency; we will consider this approach for our patient.3e5 N. Issa1*, F. Lacassin2 & F. Camou1 Medical Intensive Care and Infectious Diseases Unit, SaintAndre Hospital, CHU Bordeaux, Bordeaux; 2 Infectious Disease Department, Mont de Marsan Hospital, Mont de Marsan, France (*E-mail: nahema.issa@chu-bordeaux.fr). 1 Available online 29 June 2020 © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. https://doi.org/10.1016/j.annonc.2020.06.016 FUNDING None declared. DISCLOSURE The authors have declared no conflicts of interest. REFERENCES 1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMcp2009575. 2. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):e93ee95. 3. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5:CD013600. 4. Franchini M. Why should we use convalescent plasma for COVID-19? Eur J Intern Med. 2020;77:150e151. 5. Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815): 290e295. Does androgen deprivation therapy protect against severe complications from COVID-19? Currently, there is a paucity of effective treatments to address the remarkably high morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease-19 (COVID-19). This letter highlights a potential therapeutic strategy based on known biology of SARS-CoV-2 cellular entry and replication. SARS-CoV-2 relies on surface expression of angiotensinconverting enzyme 2 (ACE2) and transmembrane serine proteases 2 (TMPRSS2) for cellular entry and replication in the respiratory epithelium.1,2 In in vitro and mouse models, Volume 31 - Issue 10 - 2020 TMPRSS2 inhibition limits respiratory cell damage and reduces severity of infection.1,3 TMPRSS2 is commonly expressed in prostate cancer cells and is known to be regulated by androgens.4 Hence, androgen deprivation therapy (ADT) may theoretically reduce TMPRSS2 expression limiting SARS-CoV-2 cellular entry and preventing severe complications from COVID-19. In fact, a recent report from Alimonti and colleagues demonstrated a lower rate of infection in prostate cancer patients on ADT, compared with those not on ADT.5 Herein, we report our observational study of all patients in a single New York City health system with COVID-19 and prostate cancer to determine the impact of ADT on COVID-19 clinical outcomes. To our best knowledge, this is the largest study to report severity of COVID-19 in patients receiving ADT. This study was approved by the Mount Sinai School of Medicine Institutional Review Board. We identified all Mount Sinai Health System (MSHS) patients with prostate cancer and SARS-CoV-2 viral detection by PCR (based on testing within and outside MSHS) from 1 March 2020 to 4 June 2020. We collected clinical information including demographics, medical history, and medications including ADT use. ADT use was defined as a gonadotropin-releasing hormone (GnRH) analog or..
{ 'DOI': '10.1016/j.annonc.2020.06.023', 'ISSN': ['0923-7534'], 'URL': 'http://dx.doi.org/10.1016/j.annonc.2020.06.023', 'alternative-id': ['S0923753420399336'], 'assertion': [ {'label': 'This article is maintained by', 'name': 'publisher', 'value': 'Elsevier'}, { 'label': 'Article Title', 'name': 'articletitle', 'value': 'Does androgen deprivation therapy protect against severe complications from ' 'COVID-19?'}, {'label': 'Journal Title', 'name': 'journaltitle', 'value': 'Annals of Oncology'}, { 'label': 'CrossRef DOI link to publisher maintained version', 'name': 'articlelink', 'value': 'https://doi.org/10.1016/j.annonc.2020.06.023'}, { 'label': 'CrossRef DOI link to the associated document', 'name': 'associatedlink', 'value': 'https://doi.org/10.1016/j.annonc.2020.04.479'}, {'label': 'Content Type', 'name': 'content_type', 'value': 'simple-article'}, { 'label': 'Copyright', 'name': 'copyright', 'value': '© 2020 European Society for Medical Oncology. Published by Elsevier Ltd.'}], 'author': [ {'affiliation': [], 'family': 'Patel', 'given': 'V.G.', 'sequence': 'first'}, {'affiliation': [], 'family': 'Zhong', 'given': 'X.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Liaw', 'given': 'B.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Tremblay', 'given': 'D.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Tsao', 'given': 'C.-K.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Galsky', 'given': 'M.D.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Oh', 'given': 'W.K.', 'sequence': 'additional'}], 'container-title': ['Annals of Oncology'], 'content-domain': { 'crossmark-restriction': True, 'domain': ['annalsofoncology.org', 'elsevier.com', 'sciencedirect.com']}, 'created': {'date-parts': [[2020, 7, 9]], 'date-time': '2020-07-09T22:48:59Z', 'timestamp': 1594334939000}, 'deposited': { 'date-parts': [[2021, 10, 5]], 'date-time': '2021-10-05T07:21:00Z', 'timestamp': 1633418460000}, 'funder': [ {'DOI': '10.13039/100005565', 'doi-asserted-by': 'publisher', 'name': 'Janssen Biotech'}, {'DOI': '10.13039/100007659', 'doi-asserted-by': 'publisher', 'name': 'Bayer Corporation'}, {'DOI': '10.13039/100004702', 'doi-asserted-by': 'publisher', 'name': 'Baxter International'}, {'DOI': '10.13039/100004325', 'doi-asserted-by': 'publisher', 'name': 'AstraZeneca'}], 'indexed': {'date-parts': [[2022, 3, 25]], 'date-time': '2022-03-25T19:27:11Z', 'timestamp': 1648236431935}, 'is-referenced-by-count': 37, 'issn-type': [{'type': 'print', 'value': '0923-7534'}], 'issue': '10', 'issued': {'date-parts': [[2020, 10]]}, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2020, 10]]}}, 'language': 'en', 'license': [ { 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 10, 1]], 'date-time': '2020-10-01T00:00:00Z', 'timestamp': 1601510400000}}, { 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/', 'content-version': 'vor', 'delay-in-days': 365, 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}}], 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420399336?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420399336?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'member': '78', 'original-title': [], 'page': '1419-1420', 'prefix': '10.1016', 'published': {'date-parts': [[2020, 10]]}, 'published-print': {'date-parts': [[2020, 10]]}, 'publisher': 'Elsevier BV', 'reference': [ { 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'author': 'Hoffmann', 'doi-asserted-by': 'crossref', 'first-page': '271', 'journal-title': 'Cell', 'key': '10.1016/j.annonc.2020.06.023_bib1', 'volume': '181', 'year': '2020'}, { 'DOI': '10.1038/s41586-020-2012-7', 'article-title': 'A\xa0pneumonia outbreak associated with a new coronavirus of probable ' 'bat origin', 'author': 'Zhou', 'doi-asserted-by': 'crossref', 'first-page': '270', 'journal-title': 'Nature', 'key': '10.1016/j.annonc.2020.06.023_bib2', 'volume': '579', 'year': '2020'}, { 'DOI': '10.1128/JVI.01815-18', 'article-title': 'TMPRSS2 contributes to virus spread and immunopathology in the airways ' 'of murine models after coronavirus infection', 'author': 'Iwata-Yoshikawa', 'doi-asserted-by': 'crossref', 'first-page': 'e01815', 'journal-title': 'J\xa0Virol', 'key': '10.1016/j.annonc.2020.06.023_bib3', 'volume': '93', 'year': '2019'}, { 'article-title': 'Prostate-localized and androgen-regulated expression of the ' 'membrane-bound serine protease TMPRSS2', 'author': 'Lin', 'first-page': '4180', 'journal-title': 'Cancer Res', 'key': '10.1016/j.annonc.2020.06.023_bib4', 'volume': '59', 'year': '1999'}, { 'DOI': '10.1016/j.annonc.2020.04.479', 'article-title': 'Androgen-deprivation therapies for prostate cancer and risk of ' 'infection by SARS-CoV-2: a population-based study (N\xa0= 4532)', 'author': 'Montopoli', 'doi-asserted-by': 'crossref', 'first-page': '1040', 'issue': '8', 'journal-title': 'Ann Oncol', 'key': '10.1016/j.annonc.2020.06.023_bib5', 'volume': '31', 'year': '2020'}, { 'DOI': '10.1530/ERC-20-0133', 'article-title': 'Androgen hazards with COVID-19', 'author': 'Sharifi', 'doi-asserted-by': 'crossref', 'first-page': 'E1', 'journal-title': 'Endocr Relat Cancer', 'key': '10.1016/j.annonc.2020.06.023_bib6', 'volume': '27', 'year': '2020'}], 'reference-count': 6, 'references-count': 6, 'relation': {}, 'score': 1, 'short-container-title': ['Annals of Oncology'], 'short-title': [], 'source': 'Crossref', 'subject': ['Oncology', 'Hematology'], 'subtitle': [], 'title': ['Does androgen deprivation therapy protect against severe complications from COVID-19?'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'volume': '31'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit